Rangasamy Ramanathan MD, Jacob V. Aranda MD, Daniele De Luca MD, Victoria Niklas MD
{"title":"Advancing Neonatal Drug Development Through Industry–Academic Collaboration","authors":"Rangasamy Ramanathan MD, Jacob V. Aranda MD, Daniele De Luca MD, Victoria Niklas MD","doi":"10.1002/jcph.70273","DOIUrl":"10.1002/jcph.70273","url":null,"abstract":"<p>A recent review on the future of neonatology published by <i>The Lancet Child & Adolescent Health Commission</i> focused on addressing the challenges in advancing health outcomes for infants in their first month of life, which the authors rightly consider a public health problem.<span><sup>1</sup></span> To address the inherent challenges in neonatal drug development, the Commission made several key recommendations. This included fostering cross-disciplinary collaborations and engaging key opinion leaders in neonatal clinical pharmacology to leverage preclinical and translational data derived from studies of diseases with comparable biological and pathophysiological characteristics. To strengthen funding support for preclinical and translational research aimed at elucidating the mechanisms underlying neonatal diseases, and thereby improving the evidence base for research and development decision-making. It further recommended that neonatal disorders be recognized as orphan areas to encourage investment and innovation. The prioritization of clinical studies involving repurposed drugs through active collaboration and dialogue with experts in the field was also strongly endorsed.</p><p>Importantly, the Commission recognized that a potentially critical factor in realizing these recommendations is industry–academic partnerships to overcome insufficient funding in neonatology drug development and research. More specifically, the Commission proposed that the pharmaceutical industry should revise internal compliance directives in close collaboration with neonatologists to ensure alignment with the unique ethical and clinical considerations of neonatal research and care. It further suggested that strategic priorities be established through structured engagement and dialogue with key opinion leaders in the field of neonatology.<span><sup>1</sup></span> We strongly endorse these recommendations and advocate that the industry has played a vital, irreplaceable role in drug development in neonatology. Herein, we showcase industry–academic partnerships that have driven major innovations in neonatology and describe how they can be a template for further success to deliver on the Commission's recommendations.</p><p>Despite less industry-sponsored drug development in neonatology than in many other fields, such investment has enabled important breakthroughs, including the development and global adoption of surfactant<span><sup>2</sup></span> and caffeine.<span><sup>3, 4</sup></span> Surfactant was the first drug specifically developed for the treatment of neonates and reduced neonatal mortality and pulmonary air leaks by about 50%.<span><sup>5</sup></span> In the United States alone, the introduction of surfactant was associated with a 6% reduction in infant mortality.<span><sup>5</sup></span> Caffeine can also be considered one of the most cost-beneficial and effective therapies in the newborn. It has been demonstrated that premature infants who receive caf","PeriodicalId":22751,"journal":{"name":"The Journal of Clinical Pharmacology","volume":"66 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13505236/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148814630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Paridhi Gupta PhD, Mindy Magee PharmD, Vivaswath S. Ayyar PhD
{"title":"Pharmacokinetic/Pharmacodynamic Translation and Model-Informed Drug Development for Oligonucleotide Therapeutics","authors":"Paridhi Gupta PhD, Mindy Magee PharmD, Vivaswath S. Ayyar PhD","doi":"10.1002/jcph.70267","DOIUrl":"10.1002/jcph.70267","url":null,"abstract":"<p>Small interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs) have emerged as clinically validated therapeutic modalities, with approvals and late-stage development programs spanning rare genetic, neurologic, cardiovascular, metabolic, and infectious diseases. Despite these advances, oligonucleotide development presents unique challenges compared with small molecules and biologics, including rapid plasma distributive clearance, nuclease-mediated degradation, limited extrahepatic distribution, and prolonged pharmacodynamic effects driven by tissue retention and intracellular mechanisms such as RNA-induced silencing complex loading or RNase H-mediated activity. Consequently, tissue disposition and intracellular pharmacology most often govern therapeutic response more directly than plasma exposures alone, complicating conventional approaches to dose selection, efficacy prediction, and safety assessment. Model-informed drug development (MIDD) offers a quantitative framework to address these challenges through integration of preclinical, translational, and clinical data into empirical, mechanistic, and systems-level models. This review summarizes current and emerging MIDD applications in oligonucleotide therapeutics, with primary emphasis on siRNAs and complementary insights from ASOs. Approaches discussed include empirical and semi-mechanistic pharmacokinetic/pharmacodynamic (PK/PD) models, physiologically based pharmacokinetic (PBPK) frameworks describing tissue-selective biodistribution and intracellular disposition, and quantitative systems pharmacology (QSP) models linking molecular target modulation with downstream biologic and clinical responses. Collectively, these approaches have supported cross-species translation; human dose selection; clinical trial optimization; and mechanistic understanding of oligonucleotide absorption, distribution, metabolism, excretion, and pharmacology. Finally, we discuss future opportunities and remaining challenges for MIDD in oligonucleotide therapeutics, including enabling extrahepatic delivery, characterizing interindividual variability, and integrating systems-level and data-driven approaches to improve translational predictability and accelerate development of next-generation oligonucleotide medicines.</p>","PeriodicalId":22751,"journal":{"name":"The Journal of Clinical Pharmacology","volume":"66 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148809203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rosie Z. Yu PhD, John K. Diep PharmD, Xiang Gao PhD, Cecilia Arfvidsson PhD, Angelica Quartino PhD
{"title":"Clinical Pharmacology of Eplontersen, the First Approved GalNAc-Conjugated Antisense Oligonucleotide","authors":"Rosie Z. Yu PhD, John K. Diep PharmD, Xiang Gao PhD, Cecilia Arfvidsson PhD, Angelica Quartino PhD","doi":"10.1002/jcph.70276","DOIUrl":"10.1002/jcph.70276","url":null,"abstract":"<p>Eplontersen is a GalNAc-conjugated antisense oligonucleotide (ASO) approved for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy (ATTRv-PN). GalNAc conjugation enables targeted hepatic delivery and improved potency compared with unconjugated ASOs. The clinical pharmacology of eplontersen was characterized by using in vitro studies and data from three Phase 1 studies in healthy participants and one pivotal Phase 3 study in patients with ATTRv-PN. Following subcutaneous administration, eplontersen was rapidly absorbed and exhibited a biphasic pharmacokinetic (PK) profile with a terminal half-life of approximately 3 weeks, supporting once-monthly dosing. Eplontersen is highly plasma protein‑bound, distributes predominantly within the plasma compartment before receptor‑mediated tissue uptake, and is eliminated mainly via nuclease‑mediated metabolism, with minimal renal excretion of intact drug. Across integrated population PK/PKPD and exposure–response analyses at 45 mg Q4W, eplontersen exhibits predictable PK, robust PD, exposure-independent efficacy within the achieved range, and no exposure-dependent safety signals. Albeit some covariates were identified as statistically significant for population PK and population PKPD models, they were not considered clinically meaningful when taking into account the overall variability in PK, their minimal impact on TTR reduction, and the therapeutic window for eplontersen. These findings support that 45 mg Q4W is appropriate for patients with ATTRv-PN without the need for dose modification. In vitro and model-based analyses indicate low potential for clinically relevant plasma protein binding displacement and CYP- or transporter-mediated drug–drug interactions, and demonstrate no clinically meaningful effects on the QT prolongation and a predominantly non-neutralizing anti-drug antibody profile without impact on efficacy or safety.</p>","PeriodicalId":22751,"journal":{"name":"The Journal of Clinical Pharmacology","volume":"66 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13501070/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148809259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Priyanka A. Madia PhD, Emily R. Wendt PhD, Ann Ran-Ran Qin MSc, MBA, Xin Qi PhD, Yan Liang PhD, Shital Kalariya MD, Frank Hong MD, PhD, Eda Canales PhD, James G. Taylor PhD, Udayasankar Arulmani MD, Msc, PhD, Tarundeep Kakkar PhD
{"title":"First-In-Human Evaluation of the Pharmacokinetics, Pharmacodynamics, and Safety of Tilpisertib Fosmecarbil (GS-5290), an Oral Prodrug of a Tumor Progression Locus 2 Inhibitor in Healthy Participants","authors":"Priyanka A. Madia PhD, Emily R. Wendt PhD, Ann Ran-Ran Qin MSc, MBA, Xin Qi PhD, Yan Liang PhD, Shital Kalariya MD, Frank Hong MD, PhD, Eda Canales PhD, James G. Taylor PhD, Udayasankar Arulmani MD, Msc, PhD, Tarundeep Kakkar PhD","doi":"10.1002/jcph.70269","DOIUrl":"10.1002/jcph.70269","url":null,"abstract":"<p>Tilpisertib fosmecarbil (TIP; GS-5290) is an intestinally cleaved prodrug of GS-4875, a potent tumor progression locus 2 (TPL2) inhibitor being investigated for ulcerative colitis (UC). The pharmacokinetics, pharmacodynamics, and safety of single or multiple (over 10 days) oral doses of TIP (N = 73; 75-1500 mg) or GS-4875 (N = 82; 15-450 mg) were assessed in two randomized, placebo-controlled studies in healthy participants. A third study (N = 32) assessed the renal effects of GS-4875 (300 mg daily) due to observed serum creatinine increases. TIP was generally undetectable in plasma after administration, indicating rapid conversion to GS-4875. GS-4875 had a half-life of 19-29 h after TIP administration and exposure was greater than with mg-equivalent doses of GS-4875 (population mean [90% CI] AUC<sub>tau</sub> slope: 0.72 [0.59-0.85] versus 0.57 [0.47-0.67]). Inhibition of lipopolysaccharide-stimulated phosphorylated extracellular signal-regulated kinase (a TPL2 pathway pharmacodynamic biomarker) 24 h post last dose was greater with TIP versus GS-4875 dosing (>90% [TIP 300-900 mg] versus 75-80% [GS-4875 450 mg]). Investigator-assessed, study drug-related adverse events (AEs) occurred in 9.3% (5/54) of TIP recipients and 5.3% (1/19) of placebo recipients (all grade 1 severity). No serious AEs or deaths occurred. GS-4875 and TIP reduced creatinine-based estimated glomerular filtration rate (GFR; day 10 baseline-adjusted geometric least-squares means ratio [90% CI] for GS-4875/placebo: 83.3% [79.2-87.5%]); this was attributed to renal transporter inhibition rather than GFR impairment as cystatin C- and iohexol-based GFR were unchanged. These data support further development of TIP in an ongoing phase 2 trial in UC (NCT06029972).</p>","PeriodicalId":22751,"journal":{"name":"The Journal of Clinical Pharmacology","volume":"66 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148809279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Michael Bewernitz PhD, Anantha Ram Nookala PhD, Gopichand Gottipati PhD FCP, Praveen Balimane PhD, Venkateswaran C. Pillai PhD, Jeffry Florian PhD, Adarsh Gandhi PhD, Kevin Krudys PhD, David Lee PhD, Dawei Li PhD, Min Li PhD, Zhihua Li PhD, Jie Liu PhD, Rajanikanth Madabushi PhD, Grimstein Manuela PhD, Mehul Mehta PhD, Srikanth C. Nallani PhD, Nimishraj Panse PhD, Wei Qiu PhD, Sreedharan Sabarinath PhD FCP, Vishnu Sharma PhD, Li Tan PhD, Ramana Uppoor PhD, Yun Xu PhD, Hao Zhu PhD, Venkatesh Atul Bhattaram PhD
{"title":"Application of Model-Informed Approaches in Neuroscience Drug Development and Regulatory Decision-Making","authors":"Michael Bewernitz PhD, Anantha Ram Nookala PhD, Gopichand Gottipati PhD FCP, Praveen Balimane PhD, Venkateswaran C. Pillai PhD, Jeffry Florian PhD, Adarsh Gandhi PhD, Kevin Krudys PhD, David Lee PhD, Dawei Li PhD, Min Li PhD, Zhihua Li PhD, Jie Liu PhD, Rajanikanth Madabushi PhD, Grimstein Manuela PhD, Mehul Mehta PhD, Srikanth C. Nallani PhD, Nimishraj Panse PhD, Wei Qiu PhD, Sreedharan Sabarinath PhD FCP, Vishnu Sharma PhD, Li Tan PhD, Ramana Uppoor PhD, Yun Xu PhD, Hao Zhu PhD, Venkatesh Atul Bhattaram PhD","doi":"10.1002/jcph.70272","DOIUrl":"10.1002/jcph.70272","url":null,"abstract":"<p>Model-informed drug development (MIDD) approaches are being increasingly used in neuroscience drug development programs and regulatory decision-making. In this work, the authors summarize a select set of cases in neurology, psychiatry, addiction, anesthesia, and analgesia, where MIDD approaches were utilized to address critical drug development questions or fill knowledge gaps. These examples include efficacy considerations such as biomarker-clinical endpoint relationships, surrogate endpoints for accelerated approval, extrapolation of efficacy, and safety aspects such as informing driving studies. Additionally, the examples also inform optimal dosing regimen selection, dose adjustments in drug interactions, life cycle management decisions such as indication expansion, formulation switching, and informing patient population selection. Together, these examples offer insights into the utility of MIDD approaches to streamline drug development and opportunities to save costs and resources.</p>","PeriodicalId":22751,"journal":{"name":"The Journal of Clinical Pharmacology","volume":"66 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148809200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Austin Yue Feng Tan BSc, Parag Garhyan PhD, Lai San Tham PharmD
{"title":"A Review of Semi-Mechanistic HbA1c Models in People with Type 2 Diabetes: Strengths, Limitations, and Applications","authors":"Austin Yue Feng Tan BSc, Parag Garhyan PhD, Lai San Tham PharmD","doi":"10.1002/jcph.70274","DOIUrl":"https://doi.org/10.1002/jcph.70274","url":null,"abstract":"<p>Type 2 diabetes (T2D) is a chronic metabolic disorder associated with high morbidity and mortality, necessitating the urgent need for the research of novel antidiabetic compounds. Population pharmacokinetic/pharmacodynamic (PK/PD) models have been used in T2D drug development to inform dose selection for antidiabetic compounds. However, most population PK/PD models are empirical, and physiological processes (e.g., glucose-mediated hemoglobin glycation) are not routinely incorporated. Conversely, semi-mechanistic models in people with T2D incorporate some relevant physiological processes, enabling prediction of long-term glycated hemoglobin (HbA1c) using only short-term glucose and HbA1c data. Semi-mechanistic T2D models may also have improved ability for extrapolation to multiple antidiabetic drug classes. This narrative review summarizes six published semi-mechanistic models commonly used or discussed for HbA1c prediction in people with T2D: A Dynamic HbA1c EndpOint Prediction Tool (ADOPT), FPG-FSI-HbA1c (FFH), FPG-Hb-HbA1c (FHH), Integrated Glucose-RBC-HbA1c (IGRH), Weight-HbA1c-Insulin-Glucose (WHIG), and Body Weight-Directed Disease Trial (BWDDT) models. An overview of the HbA1c predictive performance is presented for four of these models (ADOPT, FFH, FHH, and IGRH models). Strengths and limitations of the six semi-mechanistic T2D models are evaluated based on model assumptions, HbA1c model predictive performance, predictive accuracy for collected biomarker data, model complexity, and computational considerations. A decision tree framework is provided for model selection. Practical strategies for model development are discussed, including approaches for incorporating different drug effects into the models. Future directions include model validation with early-phase data from various antidiabetic drug classes, and exploration of alternative implementation of disease progression models.</p>","PeriodicalId":22751,"journal":{"name":"The Journal of Clinical Pharmacology","volume":"66 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148785161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
André Dallmann PhD, Andrew Butler PhD, Sophie Fischer-Holzhausen PhD, Essam Kerwash PhD, Julia Macente PhD, Nina Nauwelaerts PhD, Sílvia M. Illamola PharmD, PhD, Karen Rowland Yeo PhD, Jane Knöchel PhD
{"title":"PBPK Models for Fetal Drug Exposure: A Critical Assessment of Current Approaches and Regulatory Readiness","authors":"André Dallmann PhD, Andrew Butler PhD, Sophie Fischer-Holzhausen PhD, Essam Kerwash PhD, Julia Macente PhD, Nina Nauwelaerts PhD, Sílvia M. Illamola PharmD, PhD, Karen Rowland Yeo PhD, Jane Knöchel PhD","doi":"10.1002/jcph.70271","DOIUrl":"https://doi.org/10.1002/jcph.70271","url":null,"abstract":"<p>Physiologically based pharmacokinetic (PBPK) modeling has emerged as a critical tool for predicting fetal drug exposure during pregnancy, accounting for the complex interplay of maternal physiological changes and placental transfer mechanisms. This review summarizes the current state of PBPK modeling in maternal-fetal pharmacology, discussing various modeling approaches, including compartmental structures and mathematical formulations for placental transfer, as well as approaches to parameterize placental drug transfer in humans. Furthermore, a regulatory perspective on the use of maternal-fetal PBPK models in submissions to the MHRA is provided. Despite advancements, significant gaps remain in understanding the variability of placental drug transfer across gestational stages and the implications of transporter activity. Future research should focus on generating robust clinical data and integrating innovative technologies, such as organ-on-a-chip systems, to enhance model accuracy. Additionally, regulatory acceptance of PBPK models will depend on the establishment of comprehensive validation frameworks. By fostering collaboration between researchers, clinicians, and regulatory bodies, PBPK modeling can advance toward safer therapeutic options for pregnant women and their developing fetuses, ultimately improving maternal-fetal health outcomes.</p>","PeriodicalId":22751,"journal":{"name":"The Journal of Clinical Pharmacology","volume":"66 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148784919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rajesh Krishna PhD, Ananth Kadambi PhD, Patrick Smith PhD, Piet H. van der Graaf PharmD, PhD, Fran Brown PhD
{"title":"Model-Informed Decision Making from Drug Discovery to Reimbursement: A Roadmap for Clinical Pharmacology in Value-Based Healthcare","authors":"Rajesh Krishna PhD, Ananth Kadambi PhD, Patrick Smith PhD, Piet H. van der Graaf PharmD, PhD, Fran Brown PhD","doi":"10.1002/jcph.70270","DOIUrl":"https://doi.org/10.1002/jcph.70270","url":null,"abstract":"<p>The transition to value-based healthcare demands more efficient, evidence-driven approaches to drug discovery, development and medical use. Clinical pharmacology is uniquely positioned to support this shift through model-informed drug development (MIDD) decision-making, integrating quantitative methods across the product lifecycle. This commentary outlines a roadmap for embedding MIDD from early drug discovery through regulatory evaluation and ultimately into reimbursement and real-world use. We highlight how pharmacokinetic/pharmacodynamic modeling, mechanistic modeling, disease progression models, patient-relevant endpoints, and real-world data will inform dose selection, optimize trial design, and reduce uncertainty in benefit–risk and cost-effectiveness assessments. Emphasis is placed on cross-stakeholder alignment, including regulators, payers, clinicians, and industry, to ensure that model-informed evidence translates into demonstrable patient and economic value. Key challenges, such as data integration, model transparency, and acceptance by decision-makers, are discussed alongside practical solutions. By advancing a lifecycle-based, quantitatively informed framework, clinical pharmacology can play a central role in delivering therapies that are not only safe and effective but also aligned with the principles of value-based healthcare.</p>","PeriodicalId":22751,"journal":{"name":"The Journal of Clinical Pharmacology","volume":"66 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jcph.70270","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148784903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Semaglutide-Induced Nonarteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Meta-Analysis","authors":"Elnaz Khani PharmD,, Hila Asham PharmD,, Aysa Rezabakhsh PhD, Shima Babaei PharmD, Taher Entezari-Maleki PharmD, PhD","doi":"10.1002/jcph.70248","DOIUrl":"https://doi.org/10.1002/jcph.70248","url":null,"abstract":"<p>Despite the recent reports of the potential association between semaglutide and nonarteritic anterior ischemic optic neuropathy (NAION), available evidence remains inconclusive. We aimed to evaluate the relative effect (RE) of NAION in individuals treated with semaglutide compared to the control group. The results of this systematic review and meta-analysis were reported according to the PRISMA guidelines. The study protocol was prospectively registered in PROSPERO with ID: CRD42025649542. A systematic search was performed on the PubMed, Embase, and Cochrane Library databases until May 18, 2026. Meta-analysis of REs with 95% confidence intervals (CI) was calculated using random-effects models. Eight observational cohort studies, involving a total of 5,916,559 participants, were included in the meta-analysis. Of these, 1,870,346 patients received semaglutide treatment, while 4,046,213 were administered non-semaglutide treatment. Compared to non-semaglutide-treated patients, semaglutide users had a higher risk of NAION (RE, 1.93; 95% CI, 1.22–3.08; I<sup>2</sup>, 91%; <i>P</i> = .01). There was a significant association between NAION risk and semaglutide use in individuals with diabetes (RE, 1.84; 95% CI, 1.21–2.80; I<sup>2</sup>, 88.26%; <i>P</i> < .01). However, the results were non-significant among overweight or obese individuals (RE, 1.68; 95% CI, 0.72–3.91; I<sup>2</sup>, 83.98%; <i>P</i> = .23). The current meta-analysis suggests a possible association between semaglutide and risk of NAION. Further randomized clinical trials are required to draw a clear conclusion.</p>","PeriodicalId":22751,"journal":{"name":"The Journal of Clinical Pharmacology","volume":"66 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148784133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Guo-Xiang Hao PhD, Yue Zhou PhD, Bo-Hao Tang PhD, Hua-Jun Zhao PhD, Wei Wei PhD, John van den Anker MD, PhD, Wei Zhao PharmD, PhD
{"title":"Clinical Pharmacology in China: Seven Decades of Progress in Discipline Development and Education","authors":"Guo-Xiang Hao PhD, Yue Zhou PhD, Bo-Hao Tang PhD, Hua-Jun Zhao PhD, Wei Wei PhD, John van den Anker MD, PhD, Wei Zhao PharmD, PhD","doi":"10.1002/jcph.70262","DOIUrl":"https://doi.org/10.1002/jcph.70262","url":null,"abstract":"<p>Clinical pharmacology serves as the central discipline supporting rational clinical medication, innovative drug research, and full-lifecycle pharmaceutical supervision. Domestic clinical pharmacology research began in the 1950s, and the field entered a period of rapid development after 1979 across three phases. This study sorts domestic disciplinary milestones and analyzes three key datasets: among the 1949 registered drug clinical trial institutions nationwide, nearly 50% are located in East China; investigational new drug applications surged from 446 (2012) to 3516 (2025); and the Center for Drug Evaluation issued 631 technical guidelines. The National Natural Science Foundation set up an independent clinical pharmacology discipline classification in 2015. The multi-tiered educational system is further elaborated: the transitional 5-year pharmacy (clinical pharmacology direction) track, standardized 5-year clinical pharmacy undergraduate programs, and clinical pharmacology-oriented postgraduate research sub-disciplines under pharmacy-related majors. Although the field has built a complete framework covering basic research, clinical practice and regulatory evaluation, critical bottlenecks persist. Clinical pharmacology is not listed as an independent major in national undergraduate and postgraduate catalogues, resulting in uneven educational standards, insufficient industry–academia integration, and striking regional gaps in disciplinary resources between eastern and inland areas. China's transitional undergraduate training model and phased regulatory improvements provide practical references for pharmaceutical regulators and educators worldwide. Targeted optimization strategies are proposed to construct unified tiered educational systems, deepen cross-stakeholder collaborative innovation, and balance regional disciplinary layouts. The sound and balanced development of clinical pharmacology will continuously advance standardized clinical medication, accelerate domestic new drug innovations, and strengthen national public health protection.</p>","PeriodicalId":22751,"journal":{"name":"The Journal of Clinical Pharmacology","volume":"66 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148784301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}